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Abstract
Hepatitis E virus (HEV) is viewed as an emerging pathogen. Many European countries, including Germany, have
observed a steep increase of notiﬁed autochthonous hepatitis E cases in recent years. Our study investigated time
trends in HEV seroprevalence in southern Germany between 2003 and 2015. A total of 3000 study sera were evenly
distributed over sampling years 2003, 2006, 2009, 2012, and 2015, two age groups (20–29 and 30–39 years) and
genders and were tested for anti-HEV IgG. Positive samples were quantiﬁed. The seroprevalence declined from 32.8%
in 2003 over 22.5% in 2006 (p < 0.001) and 22.3% in 2009 to 17.7% and 17.8% in 2012 and 2015. A higher prevalence
was found for males (p= 0.018) and the older age group (p < 0.001). Anti-HEV IgG concentrations ranged from 0.22 to
1783.19 WUmL−1. A higher median concentration (2.41 vs. 1.89 WUmL−1, p < 0.001) was found in the younger age
group. The anti-HEV IgG seroprevalence decreased since 2003 and remains constant at ~18% since 2012. A rather low
anti-HEV prevalence in young adults is indicative of a susceptible population and denotes a higher risk of HEV
infections in this age group in the future. Therefore, reduction of HEV infection sources, close monitoring, and
vigilance for proper control measures are warranted.
Introduction
The hepatitis E virus (HEV) is a single-stranded, non-
enveloped RNA virus identiﬁed in 19831. This virus in the
genus Orthohepevirus has increasingly attracted attention
since 20082,3. While there is only one known serotype,
HEV genotypes differ by their epidemiology. Initially,
HEV was associated with waterborne outbreaks in
developing countries (genotypes 1 and 2). However, since
2008, an increasing number of foodborne zoonotic
infections worldwide, caused by genotypes 3 and 4, have
been reported.
The majority of HEV infections in Europe is reportedly
caused by genotype 3 and is not travel associated. Known
animal reservoirs include pigs, wild boars, and deer.
Sources of infection are raw or undercooked meat as well
as other contaminated food4. Moreover, transfusion-
transmitted hepatitis E is well documented in several
cases5–7. The vast majority of autochthonous HEV
infections are usually asymptomatic and resolve without
any known sequelae8.
There is a continuous increase of mainly autochthonous
acute cases in Europe (e.g., 220 cases in 2010 vs. 1983
cases in 2016 in Germany; https://survstat.rki.de). How-
ever, the seroprevalence trends in various European
countries are discordant. For example, a decrease in ser-
oprevalence between 1991 and 2013 was reported for
England9, Denmark10 and Germany11,12, while in the
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Netherlands an ~7% increase of anti-HEV IgG prevalence
was reported between 2000 and 2010 among subjects
aged 18–21 years13,14.
In this study, we hypothesize that if HEV infection is re-
emerging in Europe, there should be an increase in ser-
oprevalence especially in young adults, where a large
proportion of subjects is seronegative and susceptible to
infection. Therefore, we analyzed (i) whether there has
been an increase in anti-HEV IgG prevalence among
subjects aged 20–39 years in southern Germany between
2003 and 2015 and (ii) if anti-HEV IgG concentrations
have changed or have shown age- or gender-speciﬁc
variations over this time period. To address these ques-
tions, we qualitatively and quantitatively analyzed sera of
3000 individuals from 2003, 2006, 2009, 2012, and 2015
for the presence of anti-HEV IgG.
Results
Qualitative analysis
Our results show a time-dependent decrease of the anti-
HEV IgG prevalence in the study population (Fig. 1a). The
decrease started with 32.8% (2003) over 22.5% (2006) and
22.3% (2009), ended at 17.7% (2012) and remained con-
stant at 17.8% in 2015. In total, a statistically signiﬁcant (p
< 0.001) decrease of 15.0% was observed when comparing
2003 and 2015.
When analyzing the sampling year groups according to
age or gender, we observed that the prevalences in these
groups mirrored the observed overall decrease (Fig. 1b, c).
When comparing 2003 and 2015, the decrease was sta-
tistically signiﬁcant for male (p= 0.001), female (p <
0.001), 20–29-year-old (p= 0.03), and 30–39-year-old
(p < 0.001) subjects. The slight increase of prevalence in
males as well as in the age group of 20–29 years between
2012 and 2015 was not statistically signiﬁcant (p= 0.836
and p= 0.487) (Table 1).
Apart from longitudinal changes, the anti-HEV IgG
prevalence was signiﬁcantly higher for men than women
in 2006 and 2009 (p < 0.05). For the remaining years, there
were no signiﬁcant differences between gender-speciﬁc
prevalences (Fig. 1b). Between 2003 and 2012, we
observed statistically signiﬁcantly higher prevalences for
subjects aged 30–39 years than for the younger ones
(2003: p < 0.001; 2006 borderline: p= 0.051; 2009: p=
0.002; 2012: p= 0.007). However, in 2015 there was no
signiﬁcant difference in prevalence between the age
groups (Fig. 1c).
When analyzing additional subgroups (i.e., sampling
year groups, further subdivided into gender-speciﬁc age
groups; n= 150), the largest differences in prevalence
were found between women aged 20–29 years and
men aged 30–39 years: 2003 (23.3% vs. 40.0%, p= 0.003),
2006 (14.7% vs. 29.3%, p= 0.003), 2009 (15.3% vs. 34.0%,
p < 0.001), and 2012 (11.3% vs. 22.0%, p= 0.02). Also,
higher prevalences were identiﬁed for women aged 30–39
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Fig. 1 Trend of anti-HEV IgG prevalence in 2003, 2006, 2009, 2012,
and 2015. a Overall prevalences. The chi square test with continuity
correction was used to evaluate differences between the anti-HEV IgG
prevalences of successive years. b Anti-HEV IgG prevalence and 95% CI
divided by gender. c Anti-HEV IgG prevalence and 95% CI divided into
age groups. Yrs, years
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years compared to women aged 20–29 years in 2003 (p <
0.001) and 2012 (p= 0.02). Other subgroup-speciﬁc pre-
valences only differed marginally.
When considering only gender and age groups apart
from sampling year groups, it became evident that male
subjects were more often positive for anti-HEV IgG than
females (24.5% vs. 20.8%, p= 0.018) (Fig. 2a). A similar
observation was made for subjects aged 30–39 years in
comparison to those aged 20–29 years (27.7% vs. 17.6%,
p < 0.001) (Fig. 2b).
Quantitative analysis
The absolute concentration of anti-HEV IgG was deter-
mined in all specimens that tested positive (SCR ≥ 1). The
concentration ranged from 0.22 to 178.05 WUmL−1, with
the exception of one positive sample containing an excep-
tionally high concentration of 1783.19 WUmL−1 (a woman
aged between 30 and 39 years, sampled in 2012). Figure 3
shows the distribution of concentration measurements for
each sampling year as separate box-and-whisker diagrams.
Figure 4 shows a linear regression model which was gen-
erated by ﬁtting the median concentration values for each
sampling year (1.96, 1.99, 2.14, 2.24, and 2.25 WUmL−1).
However, the model only predicted a marginal overall
annual increase of median anti-HEV IgG concentrations of
about 0.03 WUmL−1 (Fig. 4).
Table 1 Anti-HEV IgG prevalence, overall, and by age and gender (percentages and absolute numbers of positives)
2003 2006 2009 2012 2015
Overall 32.8% (197/600) 22.5% (135/600) 22.3% (134/600) 17.7% (106/600) 17.8% (107/600)
Gender
Female 34.3% (103/300) 18.7% (56/300) 18.3% (55/300) 16.7% (50/300) 16.0% (48/300)
Male 31.3% (94/300) 26.3% (79/300) 26.3% (79/300) 18.7% (56/300) 19.7% (59/300)
Age group
20–29 years 23.0% (69/300) 19.0% (57/300) 17.0% (51/300) 13.3% (40/300) 15.7% (47/300)
30–39 years 42.7% (128/300) 26.0% (78/300) 27.7% (83/300) 22.0% (66/300) 20.0% (60/300)
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Fig. 2 Gender and age group analysis. Anti-HEV IgG sorted by (a)
gender and (b) age groups. Differences in prevalence were evaluated
using the chi square test with continuity correction. Yrs, years
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Fig. 3 Distribution of anti-HEV IgG antibody concentrations by
year of specimen collection. Data are shown as box-and-whisker
diagrams. The box represents the interquartile range (IQR) between
the 25th (Q1) and 75th (Q3) percentiles and includes a median line.
Lower and upper whiskers represent Q1−1.5 × IQR and Q3+ 1.5 ×
IQR, respectively. Open data points show extreme outliers. WU, World
Health Organization units
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The evaluation of the group-speciﬁc anti-HEV IgG
concentrations showed that gender had no inﬂuence on
the overall concentration level, regardless of the sampling
year. In ﬁgures, the median value for males was 2.14 WU
mL−1 compared to that of females with 2.06 WUmL−1
(p= 0.586). When regarding age groups, the median anti-
HEV IgG concentration of subjects aged 20–29 years was
signiﬁcantly higher compared to subjects aged 30–39
years (2.41 vs. 1.89 WUmL−1, p < 0.001).
Discussion
In this study, the development of anti-HEV IgG pre-
valence and concentration was investigated in adults aged
20–39 years between 2003 and 2015 in southern Ger-
many. Our results demonstrate (i) a signiﬁcant overall
decrease of anti-HEV IgG-positive young adults, among
which men and the upper age group (30–39 years) have
the highest prevalence.
Quantitatively noticeable is (ii) a slightly increasing anti-
HEV IgG trend with an overall median annual increase of
0.03 WUmL−1. It is also remarkable that younger persons
have higher levels of antibodies than older individuals,
while there is no gender-speciﬁc difference in antibody
concentrations.
In a previous study, we found a decline of the HEV-
antibody prevalence from 20.5% in 1996 to 14.5% in 2011
by immunoblot analysis in the same region of southern
Germany11. In a recently published study, we reported
very similar ﬁgures for the whole of Germany with 18.6%
in 1998 and 15.3% in 201012. Therefore, it is tempting to
speculate that our current ﬁndings might also be gen-
eralizable for the whole of Germany. However, caution is
advisable at this point since our study was not designed to
assess the situation for the whole country and intention-
ally focused on subjects of 20–39 years of age. Compar-
ability between studies is therefore limited since the
former studies included subjects between 18 and 80 years.
Moreover, there may be some geographic regions which
do not follow the observed continuous decline, possibly
due to regional or dietary factors, as has been reported for
France15.
In Denmark, a comparable decrease of anti-HEV IgG
prevalence was observed10. Using an in-house assay, a
prevalence of 32.9% in 1983, 20.6% in 2003, and 10.7% in
2013 was found. In order to achieve more comparable
data, the specimens tested in 2013 had been re-tested by
the authors using the Wantai assay (which was also used
in the present study). The prevalence by means of the
Wantai assay was 19.8%, while all subjects which had been
tested positive by the in-house assay were found positive
by the Wantai assay as well. Although the absolute
numbers are hardly comparable to the results found
in our study, the time development seen in Denmark
is also in line with our ﬁndings10. Using the Wantai assay,
a comparable prevalence rate as well as a decrease over
time was found in the US: 21.8% in 2006 and 16.0%
in 201216.
The higher prevalence in the upper age groups may be
explained by the cumulative risk of infection over a sub-
ject’s lifetime. Multiple studies have consistently observed
this phenomenon in several geographic regions10–12,16,17.
Surprisingly, we found men signiﬁcantly more often
infected with HEV than women in our study. In contrast,
no correlation between anti-HEV IgG positivity and
gender has been detected in other seroprevalence stu-
dies10–12,16. To our knowledge, this is the ﬁrst time that a
statistically signiﬁcant gender-speciﬁc difference in anti-
HEV IgG prevalence was observed. Among the various
factors that may lead to a higher anti-HEV IgG prevalence
in male subjects, we speculate that men more often
engage in speciﬁc hobbies or professions that may pose an
elevated HEV infection risk, such as hunting or veterinary
medicine18,19. Moreover, men in Germany consume more
pork than women20, which is considered the most
important transmission route of HEV in industrialized
countries21.
For the Netherlands it was reported that the prevalence
of anti-HEV IgG in younger adults increased signiﬁcantly
(p= 0.016) from 4.3% (5/116) in 2000 to 12.7% (23/181)
in 201113. Our study investigated a comparable time
period and study group in southern Germany and allowed
us to exclude such an effect. One possible explanation for
this difference is the variability in anti-HEV IgG pre-
valence between different European countries or even
smaller geographic regions15,22.
Other authors mentioned differences in laboratory test
characteristics as a possible reason for non-comparable
and strongly varying HEV prevalence data across Eur-
opean countries17,22–24. In a previous study, we had also
observed how differences in the analytic sensitivity of a
broadly applied enzyme-linked immunosorbent assay
2003 2006 2009 2012 2015
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Fig. 4 Linear regression model with 95% CI (dashed lines) for
time-related development of median values of anti-HEV IgG
antibody concentration. WU, World Health Organization units
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(ELISA) as compared to an immunoblot resulted in dif-
fering seroprevalence estimates: for subjects between 20
and 70 years and sampled in 2011, we found 34.3% HEV
IgG positive by the former and 14.5% by the latter11.
Although such different test characteristics should not
inﬂuence the ratio between groups tested at different time
points with the same test, we decided to use the well
characterized and highly sensitive Wantai ELISA in our
study, that was additionally calibrated by using the WHO
reference reagent25.
Quantitative analyses revealed an increasing level of
anti-HEV IgG antibody concentrations over time.
Although the overall annual increase of 0.03 WUmL−1
(1.59% of the median overall antibody level) was found to
be statistically signiﬁcant, it is very likely not of any
clinical relevance.
The higher antibody concentrations detected in the
lower age group of 20–29 years may reﬂect a higher
proportion of subjects among all positives who have
recently experienced the ﬁrst HEV infection in their life-
time. Consequently, those subjects will likely have higher
anti-HEV IgG concentrations as compared to those who
had the infection in the more distant past since anti-HEV
IgG generally decreases with time26. By comparison,
gender had no inﬂuence on anti-HEV IgG antibody
concentrations. Bendall et al.27 had found no relationship
between HEV IgG concentration and (among other vari-
ables) gender. Zhang and coworkers had investigated
geometric mean concentrations (GMC) of HEV anti-
bodies in a study on subjects with naturally acquired and
vaccine-induced immunity: GMC of seropositive subjects
were stable among different age groups and between
genders28.
Our ﬁndings are in contrast to the increasing number of
notiﬁed acute HEV cases seen in many years. Hepatitis E
is a notiﬁable disease in 17 of 28 European countries29.
Four additional countries that lack a notiﬁcation system
have implemented surveillance through HEV reference
laboratories. Since 2009, many countries observed a pro-
verbial explosion of laboratory-conﬁrmed autochthonous
hepatitis E cases (2009–2014; Italy: +130%, Finland:
+250%, Hungary: +350%, England & Wales: +500%,
Germany: +615%, France: +875%)29. This common trend
cannot be denied, although cautious interpretation is
advisable due to highly variable surveillance systems and
case deﬁnitions within the European Union. In Germany,
HEV with clinical symptoms is notiﬁable as a laboratory-
conﬁrmed case, if (a) anti-HEV IgM is present, or if (b) an
IgG increase in paired samples is detected, or if (c) HEV
RNA is detected. Since there is no directive to conﬁrm a
serologically deﬁned case by RNA detection, it is con-
ceivable that part of the notiﬁed cases are actually older
infections (IgM usually persists at least 4 months)30 or
false-positive IgM results. In fact, only 40% of all samples
with positive anti-HEV IgM detection are found positive
by HEV RT-qPCR in the German HEV reference
laboratory (own unpublished data). Hence, there is good
reason to believe in at least some degree of over-reporting
of acute HEV cases. Moreover, we speculate that the
phenomenon of HEV being an emerging disease in Ger-
many is most probably due to an increased awareness of
hepatitis E as an autochthonous infection and due to the
broader availability of improved serologic test systems.
The results of our study demonstrate a signiﬁcant ser-
oprevalence decrease in young adults. These ﬁndings
indicate a strong reduction in HEV infection pressure
over the last decades. For example, in 2003 and 2006, the
younger age group in our study had virtually the same
seroprevalence rate approximately 10 years later (23% vs.
22% and 19% vs. 20%, Table 1). This reduction in HEV
infection risk is in line with results of a study on the
evolutionary history and population dynamics of HEV:
based on computational modeling, the authors propose
that genotypes 3 and 4 experienced an increase in
population size in the ﬁrst half of the twentieth
century, followed by a decline of unknown cause around
199031. A second study from Japan points in the same
direction. However, the respective model shows an
increase in HEV genotype 3 population size around
1960–1970, followed by a decline around 200032.
The number of ofﬁcially notiﬁed hepatitis E cases has
increased considerably during the past decades in Ger-
many. The respective absolute numbers reported between
2003 and 2015 are shown in Fig. 5a for three selected age
groups (20–29, 30–39, and ≥ 50 years; data source:
https://survstat.rki.de). The most prominent absolute
increase was recorded in the older age group (≥50 years).
Interestingly, the proportion of notiﬁed hepatitis E in
subjects ≥50 years has also increased considerably, while
the proportion of the age groups between 20–29 and
30–39 years has decreased continuously (Fig. 5b). A
similar trend exists in the federal state of Bavaria, where
the majority of our study samples was collected (data not
shown). This can likely be explained by the decline in
HEV infection pressure over the last decades, which
results in a higher proportion of susceptible individuals
and consecutively more notiﬁed acute cases in the older
age group in which HEV infections seem to become more
often symptomatic. This would also be in line with the
observed lower seroincidence in young adults in the last
decade. During the same period, the majority of notiﬁed
cases were males (2003: 82%, 2006: 65%, 2009: 66%, 2012:
63%, 2015: 61%). For the ﬁrst time in a seroprevalence
study on HEV, we found this gender-speciﬁc effect in
young adults aged 20–39 years. Both observations can be
summarized as an increasing general trend for men and
older people being reported with autochthonous HEV
infections33.
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It is a limitation of our study that we could only test left-
over sera of conﬁned geographic origin. Due to the study
design we cannot exclude that some samples were derived
from immunosuppressed individuals, which could mar-
ginally inﬂuence quantitative data. However, we assume
that this will not notably bias the overall quantitative and
qualitative results of the study. Also, the study specimens
were not derived from a randomized study of the whole
German population that would allow claiming prevalence
trends for the entire country. Hence, the generalizability
of our results may be limited.
In order to detect a potential selection bias, the origin of
all samples was analyzed as to the referring medical spe-
cialization. No relevant variations were found over the
years (data not shown), indicating that there were indeed
no changes in the “drainage area” of our laboratory.
Moreover, venipuncture is a frequent medical procedure
associated with a wide variety of indications. The potential
that a certain group of individuals was over-sampled,
thereby potentially biasing the results, is low. Further-
more, we can exclude a response bias, because there was
no need for the study subjects to react to a study
invitation.
In summary, our study demonstrates a decreasing anti-
HEV IgG prevalence over a decade in young adults. The
prevalence has remained constant at around 18% since
2012. The median concentration of speciﬁc antibodies
was practically the same throughout the investigated time
period. A low anti-HEV prevalence in a population is a
signiﬁcant substrate of susceptible population and might
be the “silence before a storm”: i.e. a higher rate of HEV
infections, especially in young adults in the future.
Therefore, more work is needed to elucidate and reduce
HEV infection sources and reservoirs. Moreover, close
monitoring, vigilance for proper control measures, and
comparative studies to investigate the development of
prevalence in different geographic regions will be of
importance in such conditions.
Materials and methods
Study population
The study cohort consisted of 3000 subjects between 20
and 39 years of age with residence in southern Germany.
Medical personnel were excluded in order to ensure that
the study cohort represents an acceptable surrogate to the
local general population. Apart from that, no criteria
other than the donor’s age and date of collection were
taken into account. Selection of specimens was not car-
ried out according to any speciﬁc indication but was
performed using a random sample from all available left-
over sera as described below.
Study design
The years 2003, 2006, 2009, 2012, and 2015 were chosen
as time-series for the determination of anti-HEV ser-
oprevalence. Since anti-HEV IgG prevalence increases
with age11,34,35, only subjects between 20 and 39 years
were included to better detect potential prevalence
changes. Based on previous results of anti-HEV IgG
antibody studies11, we assumed a prevalence rate of 13.4%
in 2011 for the age group of 20–39 years. An annual
prevalence increase of 0.5% was proposed as a working
hypothesis13. Using the G*Power 3.1 software36, a sample
size of 600 subjects per year was found to be necessary to
detect a statistically signiﬁcant effect with α= 0.05 and
95% statistical power.
After applying the exclusion criteria described above
and after eliminating duplicate specimens, 15,082 avail-
able samples were sorted according to sampling year, age
group (20–29 and 30–39 years), and gender. Subse-
quently, 150 samples per subgroup were randomly chosen
using the sample() function implemented by the R pro-
gramming language (R Foundation for Statistical
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Computing). By following this approach, a total of
3000 samples were selected.
Sample collection
All study specimens were obtained as part of the daily
routine operations of our diagnostic laboratory in 2003
through 2015. Only surplus serum stored at −20 °C was
used for this study.
Qualitative analysis
All samples were analyzed for anti-HEV IgG using a
commercially available (Wantai, China). The assay was
performed according to the manufacturer’s instructions.
Washing steps were executed using the automated
HydroFlex ELISA washer (TECAN, Austria). For inter-
pretation of results, all specimens with a signal-to-cut-off
ratio (SCR) ≥1 in single determination were considered
positive. Samples with an SCR <1 were considered
negative.
Quantitative analysis
To determine absolute anti-HEV IgG concentrations
and to adjust for potential product batch and interassay
variations, we used the WHO reference reagent for anti-
bodies to HEV (NIBSC code: 95/584). Calibration was
done by performing an ELISA run with a twofold refer-
ence reagent dilution series. Anti-HEV IgG concentration
started from 100 WHO Units per mL (WUmL−1) and
was diluted in 20 steps to a ﬁnal concentration of 1.91 ×
10−4 WUmL−1. The measured values showed a typical
sigmoid curve (data not shown).
The quantiﬁcation range was between 0.10 and 15.79
SCR. Only positive samples (SCR ≥ 1) were considered.
Specimens with an SCR above the quantiﬁcation range
were diluted and re-tested.
Individual calibrations of each ELISA run were imple-
mented with four standardized WHO reference reagent
dilutions covering the approximate quantiﬁcation range
(3.13, 0.78, 0.20, and 0.05 WUmL−1). The SCR values
were converted by a linear regression model using Sig-
maPlot 12.3 (Systat Software Inc., USA) and Microsoft
Excel (Microsoft Corp., USA).
Statistical methods
Statistical data analysis was performed using IBM SPSS
Statistics 23 (IBM Armonk, USA). For the evaluation of
quantitative data, the Mann–Whitney U test was used and
for the evaluation of qualitative data a chi-squared test
with continuity correction was performed. A statistically
signiﬁcant difference was deﬁned as p < 0.05. Conﬁdence
intervals (CI) of 95% were calculated with the Wilson
score interval. Statistical regression analyses were per-
formed using the R programming language (R Foundation
for Statistical Computing).
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